Division of Gastroenterology and Hepatology and Digestive Health Research Center, University of Virginia Health System, Charlottesville, Virginia 22906
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Crohn's Disease
(CD) affects more than 500,000 individuals in the United States and
represents the second most common chronic inflammatory disorder after
rheumatoid arthritis. Although major advances have been made in
defining the basic mechanisms underlying chronic intestinal
inflammation, the precise etiopathogenesis of CD remains unknown. We
have recently characterized two novel mouse models of enteritis that
express a CD-like phenotype, namely the TNF ARE model of tumor
necrosis factor (TNF) overexpression and the SAMP1/Yit model of
spontaneous ileitis. The unique feature of these models is that they
closely resemble CD for location and histopathology. These genetically
manipulated new models of intestinal inflammation offer a powerful tool
to investigate potential causes of human disease and may allow the
development of novel disease-modifying therapeutic modalities for the
treatment of CD.
ileitis; cytokines; inflammation
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
CROHN'S DISEASE (CD), one of the chronic inflammatory bowel diseases (IBD), is a debilitating disorder of unknown etiology whose incidence is on the rise worldwide (21). Although it is well recognized that the disease may involve genetic as well as environmental factors, the precise initiating events leading to CD are unknown. Therefore, therapeutic approaches for the treatment of CD are aimed at alleviating symptoms, are often nonspecific, and do not affect the natural history of the disease. One approach to investigating the pathogenic mechanisms involved in a complex disease such as CD is the use of appropriate animal models. Such an approach offers several advantages compared with direct clinical investigation of the affected patient population. For example, the time course of disease phenotype as well as specific pathophysiological events occurring before disease onset can be studied. In addition, modern technology has made it possible to perform genetic and immunologic manipulations of relevant genes that may be involved in the pathogenesis of the human disease (2). The relative contribution of bacterial and dietary antigens can also be assessed using germ-free animals, monoassociation studies with specific bacteria, as well as defined dietary regimens. Finally, specifically targeted interventions as well as experimental treatment modalities can be successfully tested in the appropriate animal model system. Ideally, an appropriate animal model for investigating IBD, particularly CD, should display an intestinal phenotype that develops spontaneously without gene targeting or immunologic manipulations (1) and should closely resemble the specific human disease. The present article briefly reviews currently available animal models of IBD and discusses in detail two novel genetically engineered murine models of experimental CD.
![]() |
OVERVIEW OF ANIMAL MODELS OF IBD |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Several animal models of intestinal inflammation/IBD have been
developed and extensively studied (3). These models are based on
chemical induction, gene targeting, or immune-cell transfer manipulations that all result in gut inflammation. Their
characteristics are described in Table 1.
One limiting factor with such models is that, with few exceptions, they
do not possess the hallmark features of IBD in regards to disease
location, histological features, or clinical course of the human
condition. However, these models may prove useful in characterizing a
specific biological mechanism of gut inflammation. Examples include the
characterization of the interleukin (IL)-1/IL-1 receptor antagonist
balance in the rabbit formalin-immune complex colitis model (5), the
role of protective factors in response to intestinal epithelial injury in the dextran sodium sulfate (DSS) colitis model (16), the key
function of regulatory T cells in the CD45RBhigh adoptive
transfer model (6), and the importance of neurogenic gut inflammation
in the dinitrobenzenesulfonic acid (DNBS) colitis model (23). These
models of intestinal inflammation/IBD, however, may have little value
in defining the precise etiopathogenesis of the human disease.
|
Chemically induced models. This group of animal models requires the administration of an exogenous chemical agent for the induction of colitis. With few exceptions, the resulting intestinal inflammation is acute and persists as long as the chemical agent is present in the gut lumen. Examples include the acetic acid model of colitis (14), the 2,4,6-trinitrobenzenesulfonic acid (TNBS) model of colitis (19), the DSS model of colitis, and the formalin-immune complex colitis model (7). These models have each generated important information on specific biochemical pathways of inflammation and have provided proof of concept for specific therapeutic interventions for the treatment of IBD. However, they are primarily characterized by acute mucosal injury (29) and clearly differ from human IBD in many aspects, including the initiating event and the clinical course of gut inflammation.
Immunologic models. Immunologically mediated models are defined as models of adoptively transferred T cells or bone marrow precursors, which are introduced into immunodeficient recipients, usually mice. The two best examples are the CD45RBhigh transfer model (20) and the bone marrow chimera transfer model (8). This group of animal models has provided very important information on the role of regulatory T cells in controlling mucosal immunity and intestinal inflammation and offers strong evidence that Th1 polarization may play a key role in the pathogenesis of CD (22). However, the profound immunological abnormality in the recipient mice, who lack a competent immune system, make these models unlikely to be suitable for investigating the precise factors involved in human CD.
Genetic models.
The advent of transgenic and knockout methodologies have revolutionized
the field of animal models of IBD after the discovery that a variety of
genetically manipulated mouse models develop chronic intestinal
inflammation. Examples include the IL-2 (26), T cell receptor
(TCR)/
(18), IL-10 (13), and Gi2
(25) knockout models. With
the exception of IL-10-deficient mice, which possess some features of
human CD (Table 2), the majority of these
models display features more similar to ulcerative colitis than CD.
These models have contributed greatly to our current understanding of
the role of key immune-related molecules and genes, including specific
cytokines, in the pathogenesis of chronic intestinal inflammation.
Collectively, these models have clearly demonstrated the requirement
for strict regulation of the mucosal immune response and have allowed
identification of key components involved in gut immune regulation.
However, it is unlikely that these mutations represent the underlying
defect in human CD. Therefore, the use of these models is limited,
particularly when they are directed at investigating causal factors of
human CD.
|
Spontaneous models. This group represents the most attractive model system of intestinal inflammation/IBD because gut disease occurs without any apparent exogenous manipulations, similar to human disease. Two animal models have been investigated and characterized in this group. The first is represented by the cotton-top tamarin model, which shows features similar to human ulcerative colitis in regards to clinical course, location of disease, histological features, increased risk of colon cancer, and response to conventional treatments (15). The second model is the C3H/HeJBir model of colitis characterized by a spontaneous and chronic focal inflammation localized to the right colon and cecal region (27). Interestingly, the colitis occurs in young mice and tends to resolve with age, without recurrence. Similar to severely immunocompromised mice, as well as some of the knockout mice, there appears to be a correlation between Helicobacter infection and the onset of colitis in the C3H/HeJBir model. However, both the C3H/HeJBir and cotton-top tamarin models of gut inflammation have similarities to human ulcerative colitis and do not involve the small intestine. Until recently, no models of spontaneous ileitis were reported.
![]() |
NOVEL MOUSE MODELS OF CROHN'S DISEASE |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
In the last three years, our group has characterized two new murine models of experimental CD that closely resemble many of the characteristics of the human disease. These models provide an exciting opportunity to attempt to define the precise etiology of CD and to begin to develop a cure for this devastating disease.
TNF ARE model of ileitis.
A large body of evidence supports the concept that tumor necrosis
factor (TNF) may play a key role in the pathogenesis of chronic
inflammatory diseases, including IBD (9). The most compelling evidence
for the importance of TNF in mediating human CD is the ability of drugs
that modulate TNF production to markedly decrease symptoms and severity
of inflammatory lesions in patients with active CD (28). On the basis
of these observations, we recently reported (10) a unique model of TNF
overexpression that develops an impressive CD-like phenotype, which
is localized primarily to the small intestine and is characterized by
chronic transmural ileitis with features very similar to human CD
(Table 2).
SAMP1/Yit model of ileitis. Another model of experimental CD that shows great promise to identify characteristics of the human disease is the SAMP1/Yit model of ileitis. This mouse line was generated by genetic manipulation involving brother-sister mating for >20 generations of the original senescence-accelerated mouse (SAM) line (17). This particular model has the unique feature of developing spontaneously without either gene targeting or immunologic manipulations. The spontaneous ileitis develops at ~20 wk of age and reaches virtually 100% penetrance after 30 wk of age. Interestingly, the ileitis characteristic of this model does not resolve with age but tends to progress in severity, up to 80 wk (unpublished results). The histological features of this model closely resemble human terminal ileitis, with segmental inflammation localized primarily to the terminal ileum. In addition, transmural inflammation, presence of mucosal and submucosal granulomas, changes in epithelial cell morphology and architecture, and muscular and neural hypertrophy are all pathologies observed in the SAMP1/Yit model (Table 2). Therefore, one of the most attractive features of this model is that all the aforementioned characteristics are hallmark events typical of human CD. Minor differences do exist, however, including the presence of sporadic macroscopic ulceration as well as the absence of pyloric metaplasia, which are usually included in the histopathological diagnosis of the human disease. Similar to other models of IBD, the chronic ileitis can be adoptively transferred by CD4+ T cells into severe combined immunodeficient (SCID) mice (11). Interestingly, the resulting disease is once again localized to the terminal ileum, suggesting that the activated CD4+ T cells may recognize antigens specifically localized to the terminal ileum.
Another feature of the SAMP1/Yit model is that Th1-polarizing cytokines, including TNF and IL-12, appear to be key mediators of the chronic gut inflammation. In fact, administration of monoclonal antibodies against both TNF and IL-12 has the ability to suppress markedly the severity of disease compared with treatment with appropriate isotype control antibodies (24). In addition, adhesion molecules, which have been implicated in T-cell homing and neutrophil trafficking, including E- and P-selectin as well as the
|
![]() |
ACKNOWLEDGEMENTS |
---|
We wish to acknowledge Drs. G. Kollias and S. Matsumoto, who
developed TNFARE and SAMP1/Yit mice, respectively. We also thank Drs. D. Kontoyiannis, S. M. Cohn, M. McDuffie, M. M. Kosiewicz, K. F. Ley, C. C. Nast, and C. A. Moskaluk for their contribution to these studies.
![]() |
FOOTNOTES |
---|
* Eleventh in a series of invited articles on Lessons From Genetically Engineered Animal Models.
The studies described in this article were supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants DK-42191, DK-55812, and DK-07769 to F. Cominelli.
Address for reprint requests and other correspondence: F. Cominelli, Div. of Gastroenterology and Hepatology, Univ. of Virginia Health System, PO Box 800708, Charlottesville, VA 22908 (E-mail: fc4q{at}virginia.edu).
Received 23 February 2000; accepted in final form 23 February 2000.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Arseneau KO, Pizarro TT, and Cominelli F. Discovering the
cause of IBD: Lessons from animal models. Curr Opin Gastroenterol.
In press.
2.
Bhan, AK,
Mizoguchi E,
Smith RN,
and
Mizoguchi A.
Colitis in transgenic and knockout animals as models of human inflammatory bowel disease.
Immunol Rev
169:
195-207,
1999[ISI][Medline].
3.
Blumberg, RS,
Saubermann LJ,
and
Strober W.
Animal models of mucosal inflammation and their relation to human inflammatory bowel disease.
Curr Opin Immunol
11:
648-656,
1999[ISI][Medline].
4.
Burns RC, Rivera-Nieves C, Moskaluk C, Kosiewicz MM, Matsumoto S,
Cominelli F, and Ley K. Adhesion molecule blockade ameliorates
active inflammation in experimental Crohn's disease (Abstract).
Gastroenterology. In press.
5.
Ferretti, M,
Casini-Raggi V,
Pizarro TT,
Eisenberg SP,
Nast CC,
and
Cominelli F.
Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis.
J Clin Invest
94:
449-453,
1994[ISI][Medline].
6.
Groux, H,
O'Garra A,
Bigler M,
Rouleau M,
Antonenko S,
de Vries JE,
and
Roncarolo MG.
A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis.
Nature
389:
737-742,
1997[ISI][Medline].
7.
Hodgson, HJ,
Potter BJ,
Skinner J,
and
Jewell DP.
Immune-complex mediated colitis in rabbits. An experimental model.
Gut
19:
225-232,
1978[Abstract].
8.
Hollander, GA,
Simpson SJ,
Mizoguchi E,
Nichogiannopoulou A,
She J,
Gutierrez-Ramos JC,
Bhan AK,
Burakoff SJ,
Wang B,
and
Terhorst C.
Severe colitis in mice with aberrant thymic selection.
Immunity
3:
27-38,
1995[ISI][Medline].
9.
Kollias, G,
Douni E,
Kassiotis G,
and
Kontoyiannis D.
On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.
Immunol Rev
169:
175-194,
1999[ISI][Medline].
10.
Kontoyiannis, D,
Pasparakis M,
Pizarro TT,
Cominelli F,
and
Kollias G.
Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies.
Immunity
10:
387-398,
1999[ISI][Medline].
11.
Kosiewicz, MM,
Krishnan A,
Shah M,
Bentz M,
Nast CC,
Matsomoto S,
and
Cominelli F.
Characterization of a new spontaneous murine model of inflammatory bowel disease (Abstract).
Gastroenterology
114:
A1012,
1998[ISI].
12.
Kozaiwa K, Kosiewicz MM, Moskaluk C, Matsumoto S, Cominelli F,
and McDuffie M. Lack of linkage between MHC haplotype and ileitis
in a spontaneous model of Crohn's Disease (Abstract).
Gastroenterology. In press.
13.
Kuhn, R,
Lohler J,
Rennick D,
Rajewsky K,
and
Muller W.
Interleukin-10-deficient mice develop chronic enterocolitis.
Cell
75:
263-274,
1993[ISI][Medline].
14.
MacPherson, BR,
and
Pfeiffer CJ.
Experimental production of diffuse colitis in rats.
Digestion
17:
135-150,
1978[ISI][Medline].
15.
Madara, JL,
Podolsky DK,
King NW,
Sehgal PK,
Moore R,
and
Winter HS.
Characterization of spontaneous colitis in cotton-top tamarins (Saguinus oedipus) and its response to sulfasalazine.
Gastroenterology
88:
13-19,
1985[ISI][Medline].
16.
Mashimo, H,
Wu DC,
Podolsky DK,
and
Fishman MC.
Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor.
Science
274:
262-265,
1996
17.
Matsumoto, S,
Okabe Y,
Setoyama H,
Takayama K,
Ohtsuka J,
Funahashi H,
Imaoka A,
Okada Y,
and
Umesaki Y.
Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain.
Gut
43:
71-78,
1998
18.
Mombaerts, P,
Mizoguchi E,
Grusby MJ,
Glimcher LH,
Bhan AK,
and
Tonegawa S.
Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice.
Cell
75:
274-282,
1993[Medline].
19.
Morris, GP,
Beck PL,
Herridge MS,
Depew WT,
Szewczuk MR,
and
Wallace JL.
Hapten-induced model of chronic inflammation and ulceration in the rat colon.
Gastroenterology
96:
795-803,
1989[ISI][Medline].
20.
Morrissey, PJ,
Charrier K,
Braddy S,
Liggitt D,
and
Watson JD.
CD4+ T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4+ T cells.
J Exp Med
178:
237-244,
1993[Abstract].
21.
Podolsky, DK.
Inflammatory bowel disease.
N Engl J Med
325:
928-937,
1991[ISI][Medline].
22.
Powrie, F.
T cells in inflammatory bowel disease: protective and pathogenic roles.
Immunity
3:
171-174,
1995[ISI][Medline].
23.
Qiu, BS,
Vallance BA,
Blennerhassett PA,
and
Collins SM.
The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis.
Nat Med
5:
178-182,
1999.
24.
Rivera-Nieves J, Pizarro TT, Matsumoto S, Moskaluk CA, and
Cominelli F. TNF and IL-12 are key mediators of ileitis in
experimental Crohn's disease (Abstract). Gastroenterology. In
press.
25.
Rudolph, U,
Finegold MJ,
Rich SS,
Harriman GR,
Srinivasan Y,
Brabet P,
Bradley A,
and
Birnbaumer L.
Gi2 protein deficiency: a model of inflammatory bowel disease.
J Clin Immunol
15, Suppl6:
101S-105S,
1995[Medline].
26.
Sadlack, B,
Merz H,
Schorle H,
Schimpl A,
Feller AC,
and
Horak I.
Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene.
Cell
75:
253-261,
1993[ISI][Medline].
27.
Sundberg, JP,
Elson CO,
Bedigian H,
and
Birkenmeier EH.
Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice.
Gastroenterology
107:
1726-1735,
1994[ISI][Medline].
28.
Targan, SR,
Hanauer SB,
van Deventer SJ,
Mayer L,
Present DH,
Braakman T,
DeWoody KL,
Schaible TF,
and
Rutgeerts PJ.
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor for Crohn's disease. Crohn's Disease cA2 Study Group.
N Engl J Med
337:
1029-1035,
1997
29.
Yamada, Y,
Marshall S,
Specian RD,
and
Grisham MB.
A comparative analysis of two models of colitis in rats.
Gastroenterology
102:
1524-1534,
1992[ISI][Medline].